Who are Steglatro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DAPA, Farxiga, Forxiga, Dapaglifozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ertugliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Steglatro — Competitive Intelligence Brief

Steglatro (ERTUGLIFLOZIN) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Low affinity sodium-glucose cotransporter Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Steglatro (ERTUGLIFLOZIN) — Merck & Co.. Steglatro works by blocking the kidneys' ability to reabsorb glucose, allowing excess glucose to be excreted in the urine.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Target	Approval / PDUFA
Steglatro TARGET	ERTUGLIFLOZIN	Merck & Co.	marketed	Low affinity sodium-glucose cotransporter	2017-01-01
DAPA	DAPA	Astrazeneca Ab	marketed	Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
Farxiga	Farxiga	AstraZeneca	marketed	Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
Forxiga	Forxiga	AstraZeneca Turkey	marketed	Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
Dapaglifozin	Dapaglifozin	MedImmune LLC	phase 3	Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Steglatro — Competitive Intelligence Brief. https://druglandscape.com/ci/ertugliflozin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab